Radiopharm Theranostics Ltd
Business
Radiopharm Theranostics Ltd is a research and development company that develops and commercializes radiopharmaceutical platforms for diagnostic and therapeutic precision oncology. It offers targeted radiopharmaceuticals and theranostic agents across molecule classes — including nanobody-based Nano-mAbs, small-molecule Pivalate and Trivehexin, monoclonal antibody platforms (PSA‑mAb, B7‑H3) and PTPµ-targeted agents — for imaging and radionuclide therapy. Key business activities include clinical development of multiple pipeline assets, licensing collaborations and a joint venture (Radiopharm Ventures LLC) to advance therapeutic products. The company pursues regulatory approvals and conducts trials across the United States, European Union, United Kingdom, China, Japan, Australia and Canada and leverages academic, supplier and contract manufacturing partnerships for development and distribution.
Summary from filing dated 2025-09-18
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-38.34M |
| Total assets | $86.48M |
| Total liabilities | $43.61M |
| Stockholders' equity | — |
| Operating cash flow | — |